Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Sep 15;60(3):2200746.
doi: 10.1183/13993003.00746-2022. Print 2022 Sep.

COVID-19 drug research and the cohort multiple randomised controlled trial design

Rafael Dal-Ré  1
Affiliations
Comment

COVID-19 drug research and the cohort multiple randomised controlled trial design

Rafael Dal-Ré. Eur Respir J. .

Abstract

In the cohort multiple randomised controlled trial design, consent is not sought from control group participants in each trial conducted within the cohort, so it is ethically inappropriate for assessment of medicinal products in COVID-19 patients https://bit.ly/3xtBX3m

Trial registration: ClinicalTrials.gov NCT04324047.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: None declared.

Comment on

References

    1. Nasrallah AA, Farran SH, Nasrallah ZA, et al. . A large number of COVID-19 interventional clinical trials were registered soon after the pandemic onset: a descriptive analysis. J Clin Epidemiol 2020; 125: 170–178. doi:10.1016/j.jclinepi.2020.06.005 - DOI - PMC - PubMed
    1. Hermine O, Mariette X, Tharaux PL, et al. . Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial. JAMA Intern Med 2021; 181: 32–40. doi:10.1001/jamainternmed.2020.6820 - DOI - PMC - PubMed
    1. CORIMUNO-19 Collaborative group . Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial. Lancet Respir Med 2021; 9: 295–304. doi:10.1016/S2213-2600(20)30556-7 - DOI - PMC - PubMed
    1. CORIMUNO-19 Collaborative group . Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): an open-label randomised controlled trial. Lancet Rheumatol 2022; 4: e24–e32. doi:10.1016/S2665-9913(21)00315-5 - DOI - PMC - PubMed
    1. Hermine O, Mariette X, Porcher R, et al. . Tocilizumab plus dexamethasone versus dexamethasone in patients with moderate-to-severe COVID-19 pneumonia: a randomised clinical trial from the CORIMUNO-19 study group. eClinicalMedicine 2022; 46: 101362. doi:10.1016/j.eclinm.2022.101362 - DOI - PMC - PubMed

Substances

Associated data

LinkOut - more resources